BVA unveils, begins to test “bionic eye”

Melbourne, Australia--Bionic Vision Australia (BVA) has unveiled a wide-view optical neurostimulator--a so-called "bionic eye" that will be implanted into Australia's first recipient of the technology.

Melbourne, Australia--Bionic Vision Australia (BVA) has unveiled a wide-view optical neurostimulator--a so-called "bionic eye" that will be implanted into Australia's first recipient of the technology.

The prototype, developed by BVA researchers at the University of New South Wales and unveiled at the BVA consortium's official launch at the University of Melbourne, will deliver improved quality of life for patients suffering from degenerative vision loss caused by retinitis pigmentosa and age-related macular degeneration.

The device, which is currently undergoing testing, consists of a miniature camera mounted on glasses that captures visual input, transforming it into electrical signals that directly stimulate surviving neurons in the retina. The implant will enable recipients to perceive points of light in the visual field that the brain can then reconstruct into an image.

Future versions may allow facial recognition
Anthony Burkitt, research director of BVA and professor of engineering at the University of Melbourne, says the device will deliver life-changing vision for recipients. "We anticipate that this retinal implant will provide users with increased mobility and independence, and that future versions of the implant will eventually allow recipients to recognize faces and read large print," he says.

BVA is a partnership of world-leading Australian research institutions collaborating to develop an advanced retinal prosthesis, or bionic eye, to restore the sense of vision to people with degenerative or inherited retinal disease. The partners of BVA are the University of Melbourne, the University of New South Wales, the Bionic Ear Institute, the Centre for Eye Research Australia, and NICTA.

In December 2009, BVA was awarded $42 million from the Australian government. The grant, provided over four years, will take the team to the point where commercial development of an implant at the back of the eye, responding to wireless transmission of vision, will become a reality.

Retinitis pigmentosa sufferer Leighton Boyd says this exciting development gives him hope that he will once again be able to see the faces of his loved ones.

--posted by John Wallace

BioOptics World

More in Neuroscience